Overview

Velcade (Bortezomib) Consolidation After Transplant

Status:
Completed
Trial end date:
2018-01-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if bortezomib when added to consolidation treatment with thalidomide and prednisolone leads to an improved response in patients with multiple myeloma who have undergone autologous stem cell transplant and initial treatment with bortezomib, cyclophosphamide, and dexamethasone.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Scientific Affairs, LLC
Treatments:
Bortezomib
Cyclophosphamide
Dexamethasone
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Thalidomide